Arafcyt en es it fr

Arafcyt Brand names, Arafcyt Analogs

Arafcyt Brand Names Mixture

  • No information avaliable

Arafcyt Chemical_Formula

C9H13N3O5

Arafcyt RX_link

http://www.rxlist.com/cgi/generic3/cytarabine.htm

Arafcyt fda sheet

http://www.accessdata.fda.gov/scripts/cder/onctools/labels.cfm?GN=cytarabine

Arafcyt msds (material safety sheet)

Arafcyt MSDS

Arafcyt Synthesis Reference

Krenitski, et al; Carbohydr.Res.; 97, 139-146(1981)

Arafcyt Molecular Weight

243.217 g/mol

Arafcyt Melting Point

212-213oC

Arafcyt H2O Solubility

Freely soluble

Arafcyt State

Solid

Arafcyt LogP

-2.712

Arafcyt Dosage Forms

Injectable solution

Arafcyt Indication

For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Arafcyt Pharmacology

Cytarabine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute myelogenous leukemia and meningeal leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Cytarabine is metabolized intracellularly into its active triphosphate form (cytosine arabinoside triphosphate). This metabolite then damages DNA by multiple mechanisms, including the inhibition of alpha-DNA polymerase, inhibition of DNA repair through an effect on beta-DNA polymerase, and incorporation into DNA. The latter mechanism is probably the most important. Cytotoxicity is highly specific for the S phase of the cell cycle.

Arafcyt Absorption

Less than 20% of the orally administered dose is absorbed from the gastrointestinal tract.

Arafcyt side effects and Toxicity

Cytarabine syndrome may develop - it is characterized by fever, myalgia, bone pain, occasionally chest pain, maculopapular rash, conjunctivitis, and malaise.

Arafcyt Patient Information

This medicine is a type of chemotherapy for treating cancers of the
blood and certain other cancers. This medicine interfers with the
way cancer cells grow, Take your doses on a regular scheduled time
and DO NOT take this medicine more often than directed by your health
care provider. Finish the full course prescribed by your health care
provider. DO NOT stop taking this medicine unless diredted to do so
by your health care provider. While taking this medicine, you make
get infection more easily. Call your doctor if you get a fever, chills,
or sore throat. Drink plenty of water with this medicine.

Arafcyt Organisms Affected

Humans and other mammals